BOROSCI

Borosil Scientific Share Price

₹182.52 +0.36 (0.2%)

21 Nov, 2024 14:19

SIP TrendupStart SIP in BOROSCI

Start SIP

Performance

  • Low
  • ₹177
  • High
  • ₹186
  • 52 Week Low
  • ₹138
  • 52 Week High
  • ₹230
  • Open Price₹180
  • Previous Close₹182
  • Volume68,605

Investment Returns

  • Over 1 Month -0.34%
  • Over 3 Month -4.28%
  • Over 6 Month + 67.83%
  • Over 1 Year + 67.83%
SIP Lightning

Smart Investing Starts Here Start SIP with Borosil Scientific for Steady Growth!

Invest Now

Borosil Scientific Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 56.2
  • PEG Ratio
  • 0.2
  • Market Cap Cr
  • 1,622
  • P/B Ratio
  • 4.4
  • Average True Range
  • 8.05
  • EPS
  • 3.25
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.38
  • RSI
  • 48.59
  • MFI
  • 69.49

Borosil Scientific Financials

Borosil Scientific Technicals

EMA & SMA

Current Price
₹182.52
+ 0.36 (0.2%)
pointer
  • stock-down_img
  • Bullish Moving Average 5
  • stock-up_img
  • Bearish Moving Average 8
  • 20 Day
  • ₹182.58
  • 50 Day
  • ₹185.71
  • 100 Day
  • ₹188.53
  • 200 Day
  • -

Resistance and Support

180.44 Pivot Speed
  • R3 194.57
  • R2 189.29
  • R1 185.72
  • S1 176.87
  • S2 171.59
  • S3 168.02

What's your outlook on Borosil Scientific?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Borosil Scientific specializes in manufacturing laboratory glassware, scientific instruments, and precision equipment. The company serves industries like pharmaceuticals, research, and education, providing high-quality products for scientific research and testing in domestic and international markets.

Borosil Scientific Ltd has an operating revenue of Rs. 421.88 Cr. on a trailing 12-month basis. An annual revenue growth of 263% is outstanding, Pre-tax margin of 8% is okay, ROE of 6% is fair but needs improvement. The company has a reasonable debt to equity of 1%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. It is currently FORMING a base in its weekly chart and is trading around 20% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 31 which is a POOR score indicating inconsistency in earnings, a RS Rating of 54 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 32 indicates it belongs to a strong industry group of Medical-Research Eqp/Svc and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Borosil Scientific Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-12 Quarterly Results
2024-08-13 Quarterly Results

Borosil Scientific F&O

Borosil Scientific Shareholding Pattern

67.87%
0.01%
0.37%
0%
22.86%
8.89%

About Borosil Scientific

  • NSE Symbol
  • BOROSCI
  • BSE Symbol
  • 544184
  • ISIN
  • INE02L001032

Similar Stocks to Borosil Scientific

Borosil Scientific FAQs

Borosil Scientific share price is ₹182 As on 21 November, 2024 | 14:05

The Market Cap of Borosil Scientific is ₹1622.2 Cr As on 21 November, 2024 | 14:05

The P/E ratio of Borosil Scientific is 56.2 As on 21 November, 2024 | 14:05

The PB ratio of Borosil Scientific is 4.4 As on 21 November, 2024 | 14:05

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23